Country: Canada
Language: English
Source: Health Canada
LAMOTRIGINE
DOMINION PHARMACAL
N03AX09
LAMOTRIGINE
100MG
TABLET
LAMOTRIGINE 100MG
ORAL
100/500
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0127134001; AHFS:
APPROVED
2011-11-22
PRODUCT MONOGRAPH PR DOM-LAMOTRIGINE Lamotrigine Tablets, USP 25 mg, 100 mg and 150 mg ANTIEPILEPTIC DOMINION PHARMACAL 6111 Royalmount Ave., Suite 100 Montréal, Québec, Canada H4P 2T4 Date of Revision: June 15, 2016 Submission Control No.: 194947 _Dom-LAMOTRIGINE Product Monograph _ _Page 2 of 48_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 13 DRUG INTERACTIONS ................................................................................................. 19 DOSAGE AND ADMINISTRATION ............................................................................. 24 OVERDOSAGE ................................................................................................................ 28 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 29 STORAGE AND STABILITY ......................................................................................... 33 DOSAGE FORMS, COMPOSITION AND PACKAGING............................................. 33 PART II: SCIENTIFIC INFORMATION .............................................................................. 34 PHARMACEUTICAL INFORMATION ......................................................................... 34 CLINICAL TRIALS ......................................................................................................... 35 DETAILED PHARMACOLOGY .................................................... Read the complete document